Antihypertensive Mechanisms of Minocycline in Resistant Hypertension

Conditions

• Hypertension, Resistant to Conventional Therapy

Eligibility Criteria

Sex

ALL

Age

18 Years - 100 Years

Healthy Volunteers

Not accepted

Interventions

• Minocycline Hydrochloride — DRUG
  Minocycline Hydrochloride 100 mg twice daily
• Placebo — DRUG
  Placebo

Study Details

The goal of this clinical trial is to learn about the mechanisms by which minocycline effect blood pressure in individuals with treatment-resistant hypertension. The main questions it aims to answer are: * To what extent does minocycline lower blood pressure? * Are such blood pressure effects mediated through changes in gut microbiota, gut leakiness, systemic inflammation, neuroinflammation, or some combination of these? Participants will be randomly assigned to treatment with minocycline or placebo, treated daily for 3 months, to evaluate these questions.

Key Dates

Start date

Jan 8, 2025

Status verified

Mar 2026

Primary completion

Jul 31, 2028

Completion

Jul 31, 2028

Study Design

Enrollment

120 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Minocycline Hydrochloride
  Minocycline hydrochloride 100 mg, administered twice daily for 3 months
• Placebo Comparator: Placebo
  Placebo administered twice daily for 3 months

Primary Outcome Measure

24-h systolic blood pressure [ Time Frame: 3 months ]

Central Contacts

• Joshua N Terrell
  352-294-8297
  [email protected]
• David B Smith
  352-294-8297
  [email protected]

Locations (1)

Find similar trials in Gainesville, FL